EPISODE · Sep 26, 2023 · 6 MIN
FDA D.I.S.C.O. Burst Edition: FDA approvals of Talvey (talquetamab-tgvs) for relapsed or refractory multiple myeloma, and Elrexfio (elranatamab-bcmm) for relapsed or refractory multiple myeloma
from FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.) · host U.S. Food and Drug Administration, Center for Drug Evaluation and Research
FDA D.I.S.C.O. Burst Edition: FDA approvals of Talvey (talquetamab-tgvs) for relapsed or refractory multiple myeloma, and Elrexfio (elranatamab-bcmm) for relapsed or refractory multiple myeloma
NOW PLAYING
FDA D.I.S.C.O. Burst Edition: FDA approvals of Talvey (talquetamab-tgvs) for relapsed or refractory multiple myeloma, and Elrexfio (elranatamab-bcmm) for relapsed or refractory multiple myeloma
No transcript for this episode yet
Similar Episodes
Apr 26, 2026 ·35m
Apr 25, 2026 ·141m
Apr 24, 2026 ·55m
Apr 23, 2026 ·54m
Apr 22, 2026 ·40m
Apr 21, 2026 ·64m